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Chemical inhibitors can help analyze dynamic cel-
lular processes, particularly when probes are active
in genetically tractable model systems. Although
fission yeast has served as an important model
system, which shares more cellular processes (e.g.,
RNAi) with humans than budding yeast, its use for
chemical biology has been limited by its multidrug
resistance (MDR) response. Using genomics and
genetics approaches, we identified the key transcrip-
tion factors and drug-efflux transporters responsible
for fission yeast MDR and designed strains sensitive
to a wide-range of chemical inhibitors, including
commonly used probes. We used this strain, along
with acute chemical inhibition and high-resolution
imaging, to examinemetaphase spindle organization
in a ‘‘closed’’ mitosis. Together, our findings suggest
that our fission yeast strains will allow the use of
several inhibitors as probes, discovery of new inhib-
itors, and analysis of drug action.
INTRODUCTION
Cell-permeable chemical inhibitors can be powerful tools to
examine dynamic cellular processes, such as cell division
(Lampson and Kapoor, 2006; Peterson and Mitchison, 2002;
Weiss et al., 2007). In many cases, these inhibitors can block
target function within minutes (or seconds), allowing the time-
scales of the perturbation to match that of the underlying cellular
mechanisms. When the inhibitors are reversible, relief from inhi-
bition can also be used to activate target function. In addition to
serving as useful research tools, chemical inhibitors can also
provide good starting points for developing new chemothera-
peutic agents (Bergnes et al., 2005). In the last two decades,
chemical probe discovery has become more efficient, in large
part due to the numerous advances in chemical library design
and high-throughput screening technology (Mayr and Bojanic,
2009). However, identifying the physiological targets and con-
firming specificity of chemical inhibitors remains very difficult,
and therefore the use and further development of many chemicalChemistry & Biology 19,probes and candidate drugs has been restricted (Burdine and
Kodadek, 2004).
We envisioned that a model system, which is compatible with
a wide array of genetic manipulations, could be developed to
address some of the challenges in chemical biology. In such
a system, a range of strategies, such as analysis of drug resis-
tance mechanisms, can be used to reveal a chemical inhibitor’s
physiological targetandaddress its specificity. Inaddition, if basic
cellular processes, for example, cell division, DNA replication,
RNA interference, and heterochromatin assembly, are conserved
between the model system and human cells, chemical tools to
analyze these processes could be developed. Furthermore, if
detailed phenotypic analysis was also readily accessible, the
inhibitor could be used to analyze complex and dynamic cellular
processes. These criteria are met by Schizosaccharomyces
pombe (fission yeast), inwhich several basic cellularmechanisms
aremore closely related to human cells thanSaccharomyces cer-
evisiae (budding yeast) (Roguev et al., 2008; Wood et al., 2002),
a more widely used model system for chemical biology. For
example, fission yeast, like human cells, has theRNA interference
pathway and epigenetically determines its centromere position
(White and Allshire, 2008). In contrast, S. cerevisiae lacks RNA
interference and defines centromere position based on DNA
sequence (Cheeseman et al., 2002). However, the use of fission
yeast for chemical probe discovery has been very limited, in large
part due to fission yeast’s robust multidrug resistance (MDR)
mechanisms (Arita et al., 2011; Wolfger et al., 2001).
Our understanding of theMDRmechanisms in fungi aremainly
based on studies in budding yeast (Moye-Rowley, 2003). In
current models, the MDR response involves overexpression of
two types of drug efflux pumps, the ATP-binding cassette
(ABC) family (Higgins, 1992) and the major facilitator superfamily
(MFS) (Sa´-Correia et al., 2009). The expression of these pumps is
believed to be regulated by zinc-finger and AP-1 transcription
factors (Moye-Rowley, 2003). In fission yeast, Bfr1 and Pmd1
have been shown to be the key ABC family transporters (Arita
et al., 2011; Iwaki et al., 2006), but theMFS transporters involved
remain unclear. Pap1, an AP-1 like transcription factor, has been
shown to have important roles in MDR (Toda et al., 1991; Toone
et al., 1998), but the zinc-finger transcription factors remain
uncharacterized. Therefore, to develop fission yeast as a model
system for chemical probe discovery and chemical biology, it is
important to analyze these mechanisms and suppress the MDR
response.893–901, July 27, 2012 ª2012 Elsevier Ltd All rights reserved 893
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C Figure 1. Analysis of Fission Yeast’s Tran-
scriptional Response to Drug Treatment
(A) Growth of wild-type cells (in YE4S medium at
32C) in the presence or absence of purvalanol
A (PurA).
(B) Microarray analysis of mRNA levels in expo-
nentially growing wild-type cells that were treated
for 20min with 20 mMPurA (or DMSO). Scatter plot
is color-coded for expression levels (green, low;
red, high). The lines show ± 2-fold change in
response to drug (n = 2 independent experiments,
average is shown). The list of genes that were
upregulated (>2-fold) by PurA treatment are
provided in Table S3.
(C–E) The expression levels of bfr1+ and pmd1+
genes in chemical inhibitor-treated exponentially
growing wild-type cells analyzed by RT-qPCR
(n = 3). (C) Cells were treated with PurA (20 mM,
0 min), and total RNA was purified at the indicated
time points. (D and E) Cells were treated with the
indicated concentration of PurA (D) or cyclohexi-
mide (CHX) (E) for 20min, after which the total RNA
was purified.
(F) Exponentially growing wild-type (WT) or pap1D
cells were treated with 20 mM PurA (or DMSO) for
20 min, after which the total RNA was purified
(n = 3). In all RT-qPCR experiments, the histo-
grams show the ratio of the genes (value of WT
was defined as one) with respect to the signals
obtained for ACT1, used as a normalization
control. Error bars indicate SD.
See also Table S3.
Chemistry & Biology
Engineering Fission Yeast for Chemical BiologyHere, we report a systematic analysis of MDR in fission yeast
using microarray, gene deletion, and gene overexpression
approaches. We identified key transcription factors and drug-
efflux transporters, and functionally characterized Mfs1, an
MFS transporter, and Prt1, a fission yeast zinc-finger transcrip-
tion factor that is a homolog of budding yeast Pdr1/3. Guided
by these data, we engineered a fission yeast strain that is sensi-
tive to a wide-range of chemical inhibitors, including several
commonly used chemical probes. Finally, we use chemical
probes and high-resolution microscopy-based phenotypic anal-
yses to examine mechanisms underlying metaphase spindle
assembly.
RESULTS
Analysis of Fission Yeast’s Basal andDrug-InducedMDR
Response
To examine fission yeast’s transcriptional response to drug
treatment, we used microarray-based analysis. Purvalanol A,
which inhibits the well-conserved cyclin-dependent kinases
(Gray et al., 1998), was selected for these studies as we had
observed that cell growth was only partly inhibited, even at
relatively high doses (20 mM) (Figure 1A), possibly due to MDR
mechanisms. We found that purvalanol A (20 mM) treatment
induced, within minutes, the expression of 100 genes (Fig-
ure 1B; Table S3 available online), including bfr1+ and pmd1+,
which represent only two of the possible 11 ABC transporters
in fission yeast. Six, of the potential 49 MFS transporters, were
also upregulated (Table S3).894 Chemistry & Biology 19, 893–901, July 27, 2012 ª2012 Elsevier LWe next focused on transcription factors involved in regulating
the expression of these different pumps that maymediate fission
yeast’s MDR response. As a readout of the drug-induced MDR
response, we focused on the transcription levels of two ABC
transporters, Bfr1 and Pmd1, for which the transcriptional
response was rapid and dose-dependent (Figures 1C and 1D)
and was also induced by cycloheximide, a protein synthesis
inhibitor (Figure 1E). Pap1, an AP-1 like transcription factor, is
needed for the oxidative stress response in fission yeast and
has been shown to have important roles in MDR (Toda et al.,
1991; Toone et al., 1998). We found that Pap1 controls the basal,
but not the drug-induced expression, of the bfr1+ and pmd1+
genes (Figure 1F), suggesting that another transcription factor
is likely to be required for the drug-induced MDR response.
To identify the fission yeast transcription factor responsible for
the drug-induced expression of the ABC transporters, we
focused on other transcription factors implicated in the fungal
MDR response. Studies in S. cerevisiae and Candida albicans
have shown that the zinc-finger transcription factor ScPdr1/3
(or CaTac1) mediates MDR through transcriptional activation of
drug efflux pumps (Coste et al., 2004; Kolaczkowska et al.,
2008; Thakur et al., 2008). To characterize the fission yeast
homologs of ScPdr1, we combined bioinformatics and pheno-
typic analyses of strains from a genome-wide gene-deletion
library (Kim et al., 2010). Of the six proteins that weremost similar
to ScPdr1, our data showed that only the deletion of a previously
uncharacterized gene, SPBC530.05 enhanced sensitivity to
cytotoxic drugs (Figure 2A). We named this transcription factor
Prt1 (Pdr1-related transcription factor 1).td All rights reserved
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Figure 2. Analysis of Transcription Factors
Regulating Fission Yeast MDR Response
(A) Serial dilutions of the indicated strains were
spotted onto YE4S plates, or YE4S plates con-
taining indicated drugs, and incubated at 29C.
(B and C) The expression levels of ABC trans-
porters were measured by RT-qPCR in the indi-
cated strains (n = 5). Total RNA was purified from
asynchronous cultures.
(D) Exponentially growing wild-type or prt1D cells
were treated with 20 mM PurA (or DMSO) for
20 min, after which total RNA was purified (n = 3).
Expression ratios are calculated as in Figure 1.
Error bars indicate SD.
See also Figure S2.
Chemistry & Biology
Engineering Fission Yeast for Chemical BiologyWe next examined if Prt1 controls the drug-induced expres-
sion of drug efflux pumps in fission yeast. Of the 11 ABC trans-
porters, only the basal expression of the bfr1+ gene was reduced
in prt1D cells (Figure 2B). The levels of the bfr1+ gene transcripts
were further reduced in prt1D pap1D cells (Figure 2C). Interest-
ingly, drug-induced expression of the bfr1+ gene, but not the
pmd1+ gene, was largely suppressed in prt1D cells (Figure 2D).
These data indicate that the Pap1 and Prt1 transcription factors
together control the basal expression levels of this important
drug efflux pump, whereas Prt1 is responsible for the induced
expression of the pump in response to drug treatment.
Analysis of Prt1-Dependent Regulation of Fission Yeast
MDR
Cells lacking the ABC transporter Bfr1 were less drug sensitive
than cells lacking this transporter and the transcription factor
Prt1 (prt1D bfr1D) (Figure 3A), suggesting that Prt1 likely regu-
lates the expression of other genes required for the MDR
response. To identify these genes, we used microarray analysis
to compare gene expression profiles between wild-type and
prt1D cells. In addition to Bfr1, two previously uncharacterized
genes, which based on bioinformatics analyses were expected
to be MFS transporters, SPAC17C9.16c (hereafter, mfs1+) and
SPBC36.03c (hereafter, mfs3+), were found to be regulated by
Prt1. Interestingly, although the drug-induced expression of
these MFS transporters was largely reduced in prt1D, their
expressionwas not dependent on Pap1 (Figures 3B, 3C, andS1).
We next examined if these twoMFS transporters contribute to
the fission yeast MDR response. Although single gene deletions
of mfs1+ or mfs3+ did not increase drug sensitivity, deletions of
bfr1+ and mfs1+ together did (Figure 3D). Interestingly, bfr1D
mfs3D increased sensitivity toward cycloheximide and purvala-
nol A, but not brefeldin A, when compared to the bfr1D strain
(Figure 3D), suggesting that Mfs3 may contribute to drug influx
as well as drug efflux. Taken together, our findings indicate
that Prt1 regulates MDR through activating the expression of at
least two drug efflux pumps, an ABC transporter (Bfr1) and an
MFS transporter (Mfs1).Chemistry & Biology 19, 893–901, July 27, 2012Using Gene Overexpression to
Identify Other Components of the
Fission Yeast MDR Response
To complement the transcriptional pro-
filing and gene-deletion-based analysesof MDRmechanisms, we analyzed genes whose overexpression
could confer drug resistance in cells lacking both the transcrip-
tion factors we characterized and also the ABC transporter
Bfr1 (prt1D pap1D bfr1D). As bfr1 mutants confer sensitivity to
brefeldin A, we used this compound for the screen. Approxi-
mately 107 transformants derived from a S. pombe cDNA library
were screened and 44 brefeldin A-resistant clones were isolated
(Table S4). Consistent with our transcpritional profiling and gene
deletion data, Pap1 and Mfs1 overexpressing clones were iso-
lated. In addition, we isolated clones in which another MFS
transporter, Caf5, was overexpressed. Caf5 overexpression
was reported to confer caffeine resistance (Benko et al., 2004).
To examine the Caf50s contribution to fission yeast MDR, we
tested sensitivity to brefeldin A, cycloheximide, and purvalanol
A. Analysis of caf5D cells revealed multidrug sensitivity that
was greater than that of wild-type cells (Figure 3E), indicating
that Caf5 is also involved in the fission yeast MDR response. In
addition, dual deletion of Mfs1 and Caf5 further increase sensi-
tivity to brefeldin A but not significantly to the other two drugs
tested, consistent with drug composition being a key determi-
nant of MDR efficiency.
Engineering a Fission Yeast Strain with Increased
Drug-Sensitivity
The fission yeast strain with maximum drug sensitivity, reported
thus far, has two ABC pumps deleted bfr1D pmd1D (Arita et al.,
2011). We used our findings to design fission yeast strains that
we anticipated could be much more sensitive to a wide range
of drugs than thebfr1Dpmd1D strain.Wefirst generated a fission
yeast strain lacking the two ABC transporters and the two MFS
transporters we characterized (bfr1D pmd1D mfs1D caf5D)
and tested sensitivity to brefeldin A, cycloheximide, and purvala-
nol A. Importantly, the deletion of the MFS pumps significantly
increased drug sensitivity of fission yeast relative to the bfr1D
pmd1D strain (Figure 4A). Combined deletions of the four
drug-pumps and Pap1 (pap1D bfr1D pmd1D mfs1D caf5D)
further enhanced drug sensitivity (Figures 4A and 4C). In addi-
tion, sensitivity to these drugs is similar in both YE-basedª2012 Elsevier Ltd All rights reserved 895
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Figure 3. Analysis of the MFS Transporters Contributing to the
Fission Yeast MDR Response
(A, D, and E) Serial dilutions of the indicated strains were spotted onto YE4S
plates, or YE4S plates containing indicated drugs, and incubated at 29C.
(B) Microarray analysis of mRNA levels in exponentially growing wild-type and
prt1D cells. Scatter plot is color-coded for expression levels (green, low; red,
high). The lines show ± 1.7-fold change in response to drug (n = 2 independent
experiments, average is shown).
(C) The expression level of mfs1+ gene was measured by RT-qPCR in the
indicated strains (n = 3). Total RNA was purified after treatment with 20 mM
PurA (or DMSO) for 20 min. Expression ratios are calculated as in Figure 1.
Error bars indicate SD.
See also Figure S1 and Table S4.
Chemistry & Biology
Engineering Fission Yeast for Chemical Biologycomplete medium and EMM-based minimal medium (Figures
S3F–S3J). To further characterize this strain, we measured
growth at different temperatures (25C, 32C, and 36C), cell-
cycle progression, and spore formation in meiosis (Figures
S3A–S3E). We found that these parameters were similar to that
measured for wild-type cells. A strain (prt1D pap1D bfr1D
pmd1D mfs1D caf5D), in which prt1+ gene was also deleted,
did not significantly further enhance drug sensitivity (Figures
4A and 4C), suggesting that Bfr1 and Mfs1 are the major targets
of Prt1 for the MDR response. However, the deletion of these six
genes resulted in weak temperature sensitivity in the absence of
drug (Figure 4B). Therefore, we reasoned that the 5-gene-896 Chemistry & Biology 19, 893–901, July 27, 2012 ª2012 Elsevier Ldeleted strain is optimal for chemical biology studies and named
it the ‘‘MDR-sup’’ (for MDR-suppressed) strain.
To better evaluate theMDR-sup strain we analyzed the toxicity
of chemical inhibitors that are commonly used in yeast research,
such as actin assembly inhibitor (latrunculin A) and benomyl-
related tubulin poisons (MBC and benomyl), or other cell-cycle
kinase inhibitors used to examine mammalian cell division,
such as Aurora kinase (hesperadin) and Mps1 kinase (reversine)
inhibitors. We found that sensitivity to latrunculin A, hesperadin,
and reversine were significantly enhanced in the MDR-sup strain
(Figure S4). The activity of benomyl-based compounds was
similar in the MDR-sup strain and the wild-type strain, suggest-
ing that these compounds are not likely to be pumped out by
ABC and MFS transporters (Figure S4). We also examined
the activity of compounds from a 1,280-member library of
diverse bioactive small molecules (LOPAC1280 [Sigma-Aldrich,
St. Louis, MO, USA], 20 mM). The number of compounds that
inhibit growth by >80% in the wild-type, the strain lacking two
ABC pumps (bfr1D pmd1D), and our MDR-sup strain was found
to be 51, 92, and 132, respectively (Figures 5A and 5B; Table S5).
As would be expected, known antifungal agents (e.g., azoles)
were equally toxic to wild-type fission yeast and the MDR-sup
strain (Figure 5C; Table S5). Enhanced toxicity, compared to
the wild-type or the bfr1D pmd1D strain was observed for inhib-
itors of proteases, kinases, and topoisomerase (Table S5), sug-
gesting that MDR mechanisms reduce the efficacy of these
compounds in wild-type cells. Interestingly, several compounds
were found whose toxicity to fission yeast would not be pre-
dicted based on their anticipated targets. These include capsa-
zepine, a vanilloid receptor antagonist, PPT, an estrogen
receptor-a agonist, and GW7647, a PPARa agonist (Figure 5D;
Table S5). It will be important to determine the targets of these
compounds as it is possible they may be unanticipated off-
targets. It is likely that the MDR-sup strain will be useful for this
analysis. Together, our data indicate that our engineered MDR-
sup strain has enhanced drug sensitivity to a wide-range of
chemical inhibitors.
Analysis of theMechanism-of-Action of Commonly Used
Chemical Probes
Many chemical inhibitors that are powerful probes of cell division
dynamics in human cells are not very effective in wild-type fission
yeast cells (Figures 6A and 6B). For example, nocodazole, an
inhibitor of microtubule polymerization, has been found to be
active in fission yeast only when a mutation in a- or b-tubulin is
present (Umesono et al., 1983). There are also studies showing
the activity of thesecompoundsat extremelyhigh concentrations.
For example, Velcade has been shown to be active at a millimolar
concentrations (Takeda et al., 2011), approximately 100,000-fold
higher than its effective dose in human cells, raising concerns
about off-target activity at these doses. Therefore, the use of the
compoundshasbeen limited in fission yeast and combiningacute
chemical perturbations with genetic manipulations and detailed
phenotypic analysis has been greatly restricted. Importantly, we
find that both nocodazole and Velcade are active in the MDR-
sup strain at 10 mM (Figures 6A and 6B), suggesting that they
could be useful tools to dissect cell division mechanisms.
We next examined the cellular phenotypes associated with
nocodazole and Velcade treatments. In the presence of Velcadetd All rights reserved
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Figure 4. Construction of the ‘‘MDR-Sup’’
Fission Yeast Strain
(A) Serial dilutions of the indicated strains were
spotted onto YE4S plates, or YE4S plates con-
taining indicated drugs, and incubated at 29C.
(B) Serial dilutions of the indicated strains were
spotted onto YE4S plate and incubated at the
indicated temperature.
(C) Exponentially growing culture (OD = 0.5) of WT
(diamond), bfr1D pmd1D (triangle), pap1D bfr1D
pmd1D mfs1D caf5D (square), or prt1D pap1D
bfr1D pmd1D mfs1D caf5D (circle) cells were
diluted 50 times in YE4S medium, treated with
indicated compounds at the indicated concentra-
tions (mM), and incubated for 14 hours at 32C.
Growth (%) is presented relative to DMSO-treated
cells.
See also Figure S3.
Chemistry & Biology
Engineering Fission Yeast for Chemical BiologyMDR-sup fission yeast cells accumulatedwith separated spindle
pole bodies (SPBs), short spindles, and condensed chromo-
some, as revealed by examining Plo1 (the fission yeast homolog
of Polo-like kinase known to concentrate at SPBs in mitosis;
Mulvihill et al., 1999) signals, tubulin distribution, and DAPI stain-
ing, respectively. This phenotype is consistent with the cells
being arrested at metaphase with bipolar spindles (Figures 6C
and 6D, left lanes), as would be expected upon proteasome inhi-
bition. Subsequent addition of nocodazole resulted in the disrup-
tion of the microtubule cytoskeleton (Figure 6C, middle lanes,
Figure S5A). The loss of spindle microtubules was also indicated
by the presence of Mad2 signals at kinetochores (Figure 6D,
middle lanes), as disruption of chromosome-spindle attach-
ments results in recruitment of spindle assembly checkpoint
components to kinetochores. Interestingly, the SPBs are
frequently clustered upon treatment with nocodazole (Figures
6C and 6D, middle lanes, Figure S5). This is surprising as fission
yeast undergoes a ‘‘closed’’ mitosis, such that the nuclear
envelop does not breakdown at the G2-M transition. The SPBs
are anchored in the nuclear envelope (Ding et al., 1997), and in
principle their separation could be maintained as the nuclear
envelope is not disrupted by nocodazole treatment. To exclude
the possibility that these results are due to nocodazole having
a target other than tubulin in the MDR-sup strain, we used
another antimicrotubule agent MBC or cold-treatment to disrupt
spindle apparatus (Gachet et al., 2008). In both conditions,
reclustering of SPBswas observed (Figure S5B). Together, these
data indicate that microtubules are needed not only for estab-
lishing SPB separation but also for maintaining SPB separation
in fission yeast.
Finally, relief from nocodazole treatment restored metaphase-
arrested cells with bipolar spindles (Figures 6C and 6D,
right lanes) within 30 min, consistent with nocodazole being
a reversible inhibitor. Together, these data indicate that the
mechanism-of-action of nocodazole and Velcade are conserved
in the MDR-sup fission yeast, and these chemical probes will
be useful for acutely inhibiting, and even activating, key
processes required for the stable propagation of genomes in
eukaryotes.Chemistry & Biology 19,DISCUSSION
Our analysis of MDR mechanisms in fission yeast have revealed
key factors needed for this response. Our studies have led to the
functional characterization of Mfs1, an MFS transporter, and
Prt1, a zinc-finger transcription factor. We show that Prt1, which
is likely to be a fission yeast homolog of S. cerevisiae PDR1 and
C. albicans Tac1, regulates the MDR response mainly through
drug-induced expression of an ABC transporter (Bfr1) and an
MFS transporter (Mfs1). Sequence comparison of S. pombe,
S. cerevisiae, and C. albicans proteins indicates that Prt1 has
two highly conserved domains (Figure S2). One of these is
a cysteine-rich motif at the N terminus and is likely to be involved
in zinc-dependent binding to DNA. The second conserved
domain is in the middle of the protein, is a part of the xenobiotic
binding domain (XBD), and likely binds to drugs and xenobiotics
(Thakur et al., 2008). Therefore, Prt1 may activate expression of
drug efflux pumps and induction of MDR via direct binding to
drugs.
Our analysis of the MDR mechanisms in fission yeast has led
to the construction of a MDR-sup strain that is sensitive to
a range of diverse chemical inhibitors. The MDR response in
fungi is highly complex, and it is likely that it is not completely
eliminated in theMDR-sup strains we have developed for at least
two reasons. First, sequence analysis predicts 11 ABC and 49
MFS transporters in fission yeast. It is likely that some of these
contribute, possibly redundantly, to the influx or efflux of chem-
ical inhibitors. Second, several studies indicate that genes
involved in ergosterol biosynthesis, vacuolar protein sorting,
and vacuolar H+-ATPase function are involved in MDR mecha-
nisms (Parsons et al., 2004, 2006) (Dawson et al., 2008). We
note that although deletion of Erg6, a gene in ergosterol biosyn-
thetic pathway, can increase drug sensitivity in budding yeast,
fission yeast strains with erg6 deleted are sick, even in the
absence of drugs (Iwaki et al., 2008). Therefore, we did not
examine deletions of genes in ergosterol biosynthetic pathway
to further enhance drug-sensitivity of the MDR-sup strain.
Although further analysis is needed to more completely charac-
terize the fission yeast MDR response, our findings do suggest893–901, July 27, 2012 ª2012 Elsevier Ltd All rights reserved 897
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Figure 5. The ‘‘MDR-Sup’’ Fission Yeast
Strain Is Sensitive to aWide Range of Chem-
ical Inhibitors
(A and B) Scatter plot shows growth of WT (A) or
bfr1D pmd1D (B) strain (x axis) and MDR-sup
strain (pap1D bfr1D pmd1D mfs1D caf5D) (y axis)
treated with compounds in the LOPAC 1280 library
(20 mM, Sigma-Aldrich), normalized to the growth
measured in DMSO alone. Black circles indicate
compounds that inhibit growth by >80%.
(C) Representative chemical structures of com-
pounds that inhibit growth by >90% in both WT
and MDR-sup strain.
(D) Representative chemical structures of com-
pounds that inhibit growth by >90% in MDR-sup
but by <10% in WT strain. The full list of com-
pounds that inhibit growth >80% in either WT,
bfr1D pmd1D, or MDR-sup strain is shown in
Table S5.
See also Figure S4.
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suppressed by the deletion of two ABC transporters, two MFS
pumps, and a transcription factor, indicating that these are likely
to be the key mechanisms.
Our MDR-sup strain should be particularly useful for analyzing
mechanisms of drug action. In addition to detailed phenotypic
analyses, for which a wide-range of strains and reagents are
available, classical yeast forward genetics can also be used to
analyze drug resistance mechanisms and thereby identify the
physiologically relevant drug targets. The MDR-sup strain
provides an important advantage for a random mutagenesis-
mediated selection of drug resistance. It has been show that
a very most common mechanism of drug resistance involves
the MDR response. For example, ‘‘activating’’ mutations in tran-
scription factors can lead to the overexpression of drug efflux
pumps (Moye-Rowley, 2003). As our MDR-sup (or combined
with deletion of prt1 gene) strain lacks many of these genes, it
is more likely that the drug-resistant clones isolated will have
mutations in the direct drug target of cellular pathways. The
MDR-sup strain is also likely to be useful for identifying new
chemical probes as high-throughput screens can be carried
out at lower compound concentrations than would be needed
when using wild-type strains. In addition, powerful screens,
such as ‘‘chemical synthetic lethality’’ screens, can be designed
in fission yeast to select compounds that elicit genotype898 Chemistry & Biology 19, 893–901, July 27, 2012 ª2012 Elsevier Ltd All rights reservedspecific-effects (Nehil et al., 2007;
Torrance et al., 2001). It is possible that
such screens will lead to new probes
for RNA interference and heterochro-
matin formation, processes that are
conserved between fission yeast and
humans.
The MDR-sup strain allows the use of
chemical inhibitors to be combined with
high-resolution imaging and other genetic
manipulations to dissect dynamic cellular
mechanisms. Our studies with Velcade
and nocodazole suggest that maintainingthe separation of spindle pole bodies (SPBs), key organizers of
spindle microtubules in dividing fission yeast cells, depends on
microtubules (Figure 6). This observation is surprising, as in
current models the major pulling and pushing forces acting on
the SPBs depend on microtubules and motor proteins (e.g., ki-
nesin-5) (Dumont and Mitchison, 2009). Once separated, the
SPBs could be kept apart by the nuclear envelop, in which the
SPBs are embedded (Ding et al., 1997). We favor the model in
which another, microtubule-independent, force brings the two
SPBs together. However, at this stage, we cannot exclude other
possibilities, such as the presence of microtubules that cannot
be readily detected or if SPBs are clustered during microtubule
disassembly, that is, being ‘‘reeled-in’’ by shrinkingmicrotubules
that somehow maintain attachments to chromosomes and
SPBs. Characterizing the molecular basis of this SPB cluster-
ing mechanism is an important step for future studies, as it
could shed new light on how metaphase spindles assemble
and how the size of these structures is determined in different
contexts.
Our MDR-sup strain should help analyze cellular processes
that have been difficult to study using available approaches.
For example, it is likely that our system will be useful to examine
the first and second meiotic cell divisions, which occur sequen-
tially after one round of DNA replication. The successful com-
pletion of these basic cellular processes is required to prevent
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Figure 6. Examining Mitotic Mechanisms Using Nocodazole and
Velcade in the ‘‘MDR-Sup’’ Strain
(A and B) Exponentially growing culture (OD = 0.5) of WT (black diamond) and
pap1D bfr1D pmd1D mfs1D caf5D (red square) cells were diluted 50 times in
YE4S medium, treated with indicated compounds at the indicated concen-
trations (mM), and incubated for 14 hours at 32C. Growth (%) is presented
relative to DMSO-treated cells.
(C and D) Cells were blocked at S-phase using hydroxyurea, incubated for
30 min, then treated with Velcade (40 mM), and incubated for 60 min at 32C
(+ Velcade, left lanes). Then nocodazole (15 mM) was added, and incubated for
30 min at 32C (+ nocodazole, middle lanes). After that, nocodazole was
washed out, and incubated for 30 min at 32C (wash out nocodazole, right
lanes). Representative images of Mcherry-tubulin (C), Mad2-mcherry (D), and
Plo1-mYFP (C and D) signals are shown. Scale bars, 2 mm.
See also Figure S5.
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Chemistry & Biology 19,pregnancy loss and developmental defects in humans (Hassold
and Hunt, 2001). As high or low temperature severely affects
meiotic progression in fission yeast, canonical temperature-
sensitive genetic mutants have not been very useful. Moreover,
as mechanisms of cell-cycle progression are likely to be
conserved between meiosis I and II, genetic mutations of cell-
cycle or chromosome segregation genes can affect meiosis I,
making proper interpretations of any observed perturbations
on meiosis II very difficult. We believe that the MDR-sup strain
and a validated set of chemical inhibitors, which will allow acute
inhibition, should help examine molecular mechanisms required
for the first or the second meiotic divisions.
SIGNIFICANCE
Fission yeast is a genetically tractable model system that
has provided valuable insights into cellular mechanism.
Importantly, fission yeast shares more processes (e.g.,
RNAi and centromere specification) with human cells than
budding yeast, another widely used model system. How-
ever, fission yeast has not been very useful for chemical
biology, as many commonly used chemical probes are not
active in these cells, in large part due to an effective multi-
drug resistance (MDR) response. With the goal to develop
fission yeast for chemical biology, we systematically
analyzed drug-pumps and transcription factors usingmicro-
array-based, gene deletion, and gene overexpression ap-
proaches. These studies led to two ABC transporters (Bfr1
and Pmd1), two MFS pumps (Mfs1 and Caf5), and two tran-
scription factors (Prt1 and Pap1) as the major contributors
to fission yeast’s MDR response. These findings represent
the functional characterization of Mfs1, an MFS transporter,
and Prt1, a zinc-finger transcription factor that is a homolog
of budding yeast Pdr1/3. Guided by these data, we engi-
neered the MDR-sup fission yeast strain, which has five of
these MDR genes deleted. We show that this strain is sensi-
tive to a wide-range of bioactive small molecules, including
nocodazole and Velcade. We combined the use of chemical
inhibitors, high-resolution imaging, genetic manipulations,
and the MDR-sup strain to examine metaphase spindle
assembly during mitosis. Our analysis suggests that micro-
tubules are needed to maintain the normal separation of the
twomicrotubule-organizing spindle pole bodies in a ‘‘closed
mitosis,’’ when the nuclear membrane persists through
M-phase and encapsulates the division apparatus. To-
gether, our findings indicate that our MDR-sup strain will
be useful for analyzing complex and dynamic cellular pro-
cesses. In addition, our studies suggest that fission yeast
should be a valuable genetically tractable model system
for chemical inhibitor discovery and analysis of drug mech-
anism of action.
EXPERIMENTAL PROCEDURES
Schizosaccharomyces pombe Strains
All strains used are listed in Table S1. Standard growth conditions and
methods were used (Moreno et al., 1991). Deletions of each gene in
S. pombe were performed using the PCR-based gene-targeting method for
S. pombe (Ba¨hler et al., 1998). For the Figure 2A experiment, strains from
the deletion library were used (Kim et al., 2010).893–901, July 27, 2012 ª2012 Elsevier Ltd All rights reserved 899
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Cycloheximide, nocodazole, MBC, and benomyl were purchased from Sigma-
Aldrich. Brefeldin A and Velcade (bortezomib) were purchased from
LC Laboratories (Woburn, MA, USA). Purvaranol A and latrunculin A
was purchased from Tocris Bioscience (Ellisville, MO, USA). Reversine was
purchased from Cayman Chemical (Ann Arbor, MI, USA). Hesperadin was
synthesized in our laboratory. All chemicals were dissolved in DMSO, kept in
20C, and used as 0.25%–1% DMSO solution.
Purification of Total RNA from Fission Yeast
Total RNA was isolated from S. pombe cells using a hot phenol method fol-
lowed by phenol-chloroform extraction, precipitation, and purification using
Qiagen RNeasy columns (Venlo, the Netherlands) (Lyne et al., 2003).
RT-qPCR Analysis
Total RNA (1 mg ) was used for RT reactions. RT reactions were carried out
using the manufacturer’s protocol in the presence or absence of enzyme
(SuperScript III First-Strand Synthesis System, Invitrogen, Carlsbad, CA,
USA). For quantitative PCR (qPCR), SYBR Green (Applied Biosystems, Foster
City, CA, USA) and primers were mixed, and the starting quantity of DNA was
estimated from the number of cycles (Ct value) required to reach the threshold
using Roche LightCycler 480 System (Indianapolis, IN, USA). Primers used in
this study are listed in Table S2.
Microarray Analysis
RNA quality was assessed using the Agilent 2100 Bioanalyzer and the RNA
6000 Nano kit (Agilent Technologies, Santa Clara, CA, USA). Total RNA
(200 ng) was used to prepare biotin-labeled RNA using Ambion MessageAmp
Premier RNA Amplification Kit (Applied Biosystems). Briefly, 200 ng of total
RNA was used to synthesize the first strand of cDNA using ArrayScript
reverse-transcriptase and an oligo (dT) primer bearing a T7 promoter. The
single-stranded cDNA was then converted into a double-stranded DNA
(dsDNA) by DNA polymerase I in the presence of Escherichia coli RNase H
and DNA ligase. The dsDNA was used as a template for in vitro transcription
in a reaction containing biotin-labeled UTP, unlabeled NTPs, and T7 RNA poly-
merase. The amplified, biotin-labeled antisense RNA (aRNA) was purified, and
its quality was assessed using the Agilent 2100 Bioanalyzer and the RNA 6000
Nano kit. The fragmented aRNA (4 mg) was fragmented and hybridized to
Affymetrix Yeast Genome 2.0 arrays for 16 hr at 45C as described in the
manufacturer’s protocol (Affymetrix, Santa Clara, CA, USA). After hybridiza-
tion, arrays were stained with streptavidin-phycoerythrin, followed by an
antibody solution (antistreptavidin) and a second streptavidin-phycoerythrin
solution, with all liquid handling performed by a GeneChip Fluidics Station
450. Gene Chips were then scanned with the Affymetrix GeneChip Scanner
3000 7G. The raw intensity data of Gene Chips was normalized and further
analyzed in GeneSpring 11.0 (Agilent Technologies).
Overexpression Screen
A Gateway-compatible Lifetech library was constructed from total S. pombe
RNA derived from mitotic, meiotic, and shmooing cells in a 2:1:1 ratio, within
a Gateway-modified version of the ura4-based pRep4X vector (Fersht et al.,
2007). The library was transformed into SAK31 cells. The transformed cells
were plated out and left to grow at 32C on EMM-Uri plates. The colonies
were replica-plated onto EMM-Uri plates containing 10 mM brefeldin A and
incubated at 32C. We screened 1.53 105 colonies and identified 44 colonies
as brefeldin A-resistant. The plasmids conferring brefeldin A resistance were
sequenced.
Chemical Screen
SAK1, SAK27, and SAK84 strains were used for chemical screen. Logarithmi-
cally growing cells (OD = 0.2) were diluted 16 times, mixed with compounds
(LOPAC1280, 20 mM), and incubated for 18 hr at 29C (total volume: 50 ml
per well). Multidrop Combi (Thermo Scientific, Waltham, MA, USA) was used
to dispense the cells into wells of the 384-plate (Greiner clear, flat-bottom
PS plate). The growth was measured by microtiter plate reader (Perkin-Elmer
EnVision, 590 nm filter). For calculation of growth ratio, OD values of each well
were divided by that of control well incubated with DMSO.900 Chemistry & Biology 19, 893–901, July 27, 2012 ª2012 Elsevier LMicroscopy
For methanol fixation, cell pellet from 1 ml culture is mixed with 800 ml chilled
methanol and incubated for >12 hr at 20C. The fixed cells are mixed with
DAPI (4,6-diamidino-2-phenylindole), and cell pellet are dissolved in PEMS
(100mMPIPES [pH 6.9], 1 mMEGTA, 1mMMgSO4, and 1MSorbitol). Images
were acquired at room temperature on a microscope (Axioplan 2; Carl Zeiss,
Inc., Maple Grove, MN), equipped with a CoolsnapHQ camera (Roper Scien-
tific, Trenton, NJ, USA), and were processed with MetaMorph software
(Molecular Devices, Sunnyvale, CA, USA). A Z-stack of about 3 mm thickness,
with single planes spaced by 0.3 mm, was acquired and subsequently pro-
jected to a single image.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and five tables and can
be found with this article online at http://dx.doi.org/10.1016/j.chembiol.2012.
06.008.
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